Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

AbbVie

Status

Completed

Conditions

Arthritis, Juvenile Rheumatoid

Study type

Observational

Funder types

Industry

Identifiers

NCT01412021

P12-769

Details and patient eligibility

About

This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug:

Unknown adverse drug reactions (especially important adverse drug reactions)
Incidence and conditions of occurrence of adverse reactions in the clinical setting
Factors that may affect the safety and effectiveness of Humira

Enrollment

375 patients

Sex

All

Ages

Under 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey

Exclusion criteria

Contraindications according to the Package Insert
Patients who have serious infections
Patients who have tuberculosis
Patients with a history of hypersensitivity to any ingredient of Humira
Patients who have demyelinating disease or with a history of demyelinating disease
Patients who have congestive cardiac failure